EP3322708A1 - Procédé de purification de l'idélalisib - Google Patents

Procédé de purification de l'idélalisib

Info

Publication number
EP3322708A1
EP3322708A1 EP16738171.4A EP16738171A EP3322708A1 EP 3322708 A1 EP3322708 A1 EP 3322708A1 EP 16738171 A EP16738171 A EP 16738171A EP 3322708 A1 EP3322708 A1 EP 3322708A1
Authority
EP
European Patent Office
Prior art keywords
idelalisib
acid addition
addition salt
salt
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16738171.4A
Other languages
German (de)
English (en)
Inventor
Libor Vyklicky
Miroslav Zabadal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Publication of EP3322708A1 publication Critical patent/EP3322708A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates to the preparation of pharmaceuticals.
  • it relates to a stable acid addition salt of idelalisib (1) and its use as intermediate in a purification process for idelalisib.
  • Idelalisib (WO2005113556) is a ⁇ 3 ⁇ inhibitor of structure (1) and is used for the treatment of patients with follicular lymphoma, relapsed small lymphocytic lymphoma and relapsed chronic lymphocytic leukaemia.
  • WO2005113556 describes the preparation of idelalisib as depicted below,
  • WO2013134288 describes polymorphic forms of idelalisib.
  • One of the examples for preparing polymorphic form I of idelalisib uses the hydrochloride salt of idelalisib as intermediate.
  • the hydrochloride salt is however not isolated, nor is it used as a means to purify idelalisib.
  • the hydrochloride salt is prepared by treating idelalisib with 12N hydrochloric acid in an ethanol/water mixture. The resulting salt is described as a suspension and is not isolated, but treated with aqueous base to convert the salt back into idelalisib free base and further processed to prepare polymorphic form I crystals of idelalisib as a free base.
  • the present invention relates to a process for purifying idelalisib of formula (1),
  • the salt is a salt of idelalisib with hydrochloric or nitric acid. Most preferred is the salt with nitric acid.
  • the first object of the invention is a process for purifying idelalisib comprising the step of isolating an acid addition salt of idelalisib.
  • idelalisib does not form solid acid addition salts easily, we found that precipitation or crystallisation of idelalisib in salt form, if formed, is an effective method to reduce the impurity level.
  • the method is more convenient and economic on an industrial scale than the chromatography process of WO2005113556.
  • hydrochloride and nitrate were particularly isolable in good yields.
  • the hydrochloric or nitric acid addition salts of idelalisib are the preferred salts to be used in the purification process of this invention. Most preferred is the nitrate salt.
  • Idelalisib nitrate has surprisingly low hygroscopicity when compared to the other acid addition salts which may take on water when exposed to moisture.
  • the preferred solvents for preparing the acid addition salts of idelalisib are solvents or solvent mixtures comprising an ether and/or a halogen containing solvent.
  • ethers are: diethyl ether, THF, 2-Me-THF and dioxanes.
  • Typical examples of halogen containing solvents are dichloromethane, chloroform and dichloroethane. More preferred are solvents or solvent mixtures comprising ethers and/or halogen containing solvents with a boiling point above 50°C. Most preferred are solvents or solvent mixtures comprising 1 ,4-dioxane and/or chloroform.
  • the salts of idelalisib can be prepared by adding a sufficient amount of acid to idelalisib.
  • the acid can be added to a reaction mixture comprising idelalisib after workup of a reaction mixture comprising idelalisib, or it can be added after isolation of raw idelalisib.
  • Precipitation or crystallisation of the nitric acid salt of idelalisib can start spontaneously or may be induced by methods common in the art. Typical examples of such methods to induce precipitation or crystallisation are: allowing a warm solution to cool down, addition of anti solvent to the solution, concentration of a solution, addition of seed crystals, and combinations of these methods.
  • idelalisib Treatment of idelalisib, with an assay of 88%, with 1 equivalent of nitric acid leads to formation of a nitrate salt of idelalisib with 97.8 % purity. If the precipitation/crystallisation of the idelalisib salt does not immediately lead to the desired purity level, the material may be recrystallised, or treated with base to repeat the process leading to precipitation or crystallisation of the idelalisib salt to increase the purity level.
  • the material can be treated with base to liberate idelalisib free base with an increased purity level.
  • Procedures and materials to use for liberating idelalisib from its acid addition salt are generally known to the skilled artisan.
  • Idelalisib hydrochloride is a hygroscopic compound and needs to be protected from moisture if stored for a longer period of time. Other salts have also showed hygroscopicity. Hygroscopic compounds are less attractive for use as active ingredients in pharmaceutical dosage forms. They are difficult to handle since costly and burdensome measures must be taken to prevent exposure to moisture during formulation since water may affect stability and decrease bioavailability.
  • idelalisib nitrate is not hygroscopic and stable in storage, which additionally makes it a viable alternative active ingredient to use in pharmaceutical dosage forms.
  • the solubility of idelalisib nitrate is higher compared to idelalisib as a free base and may allow preparation of pharmaceutical dosage forms with improved aqueous dissolution properties and higher bioavailability levels that are not realisable with the less soluble free base of idelalisib.
  • Purity levels in the examples are levels as determined by uncalibrated HPLC with UV detection.
  • idelalisib hydrochloride 0.036g was mixed with 3 ml of 1,4-dioxane and 0.015 ml of hydrochloric acid (35%). The mixture was heated to 90°C and allowed to cool to 20°C. The precipitate was isolated to yield 0.030 g (77%) of idelalisib hydrochloride.
  • idelalisib hydrochloride 0.036g was mixed with 3 ml of 1,4-dioxane and 7.57 ⁇ of hydrochloric acid (35%). The mixture was heated to 90°C and allowed to cool to 20°C. The precipitate was isolated and dried in a vacuum oven (100 torr, 25°C) to yield 0.035 g (85%) of idelalisib hydrochloride.
  • idelalisib 0.036g was mixed with 3 ml of 1,4-dioxane and 5.94 ⁇ of nitric acid (65%). The mixture was heated to 90°C and allowed to cool to 20°C. The precipitate was isolated to yield 0.025 g (60.9%) of idelalisib nitrate.
  • Example 4 Preparation of idelalisib nitrate
  • idelalisib 0.138g was mixed with 3 ml of chloroform and 0.023 ml of nitric acid (65%). The mixture was heated to 55°C and cooled to 0°C. The precipitate was isolated to yield 0.160 g (100%) of idelalisib nitrate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un nouveau procédé de purification de l'idélalisib (1). Le procédé comprend les étapes de création d'un sel d'addition d'acide de l'idélalisib et de précipitation ou de cristallisation d'un tel sel.
EP16738171.4A 2015-07-13 2016-07-12 Procédé de purification de l'idélalisib Withdrawn EP3322708A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2015065980 2015-07-13
PCT/EP2016/066532 WO2017009333A1 (fr) 2015-07-13 2016-07-12 Procédé de purification de l'idélalisib

Publications (1)

Publication Number Publication Date
EP3322708A1 true EP3322708A1 (fr) 2018-05-23

Family

ID=56409099

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16738171.4A Withdrawn EP3322708A1 (fr) 2015-07-13 2016-07-12 Procédé de purification de l'idélalisib

Country Status (2)

Country Link
EP (1) EP3322708A1 (fr)
WO (1) WO2017009333A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ629684A (en) * 2012-03-05 2016-10-28 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
WO2015095605A1 (fr) * 2013-12-20 2015-06-25 Gilead Calistoga Llc Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
ES2685252T3 (es) * 2014-12-09 2018-10-08 Ratiopharm Gmbh Sal de idelalisib
WO2016108206A2 (fr) * 2014-12-31 2016-07-07 Dr. Reddy’S Laboratories Limited Procédés de préparation d'idélalisib et de ses intermédiaires

Also Published As

Publication number Publication date
WO2017009333A1 (fr) 2017-01-19

Similar Documents

Publication Publication Date Title
KR101391132B1 (ko) 결정형 미노사이클린 염기 및 이의 제조방법
JP2016537346A5 (fr)
WO2017008773A1 (fr) Formes cristallines d'acide obéticholique
CN101568526B (zh) 阿那曲唑的纯化方法
EP2612855B1 (fr) Nouveau cristal d'erlotinib sous forme de base et son procédé de préparation
EP3564224B1 (fr) Form cristalline de vortioxetine hydrobromide comme medicament antidepresseur
CN106748818A (zh) 重酒石酸间羟胺的合成方法
EP3100735B1 (fr) Sel de dicyclohexamine fosaprépitant cristallin et sa préparation
US20180009831A1 (en) Process for the preparation of novel polymorphic forms of 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole
WO2012028861A1 (fr) Erlotinib pur
WO2016199824A1 (fr) Cristal de 6-bromo-3-hydroxy-2-pyrazinecarboxamide et son procédé de production
KR20160110517A (ko) 인돌린 화합물의 제조 방법
WO2018127526A2 (fr) Nouvelles formes solides de [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tétrahydrofuran-2-yl]propyl] acétate
WO2017021975A1 (fr) Procédé de préparation de formes cristallines de rifaximine
CA3108007C (fr) Forme d1 de sel de monoethanolamine eltrombopag cristalline hautement stable
WO2017009333A1 (fr) Procédé de purification de l'idélalisib
US10538493B2 (en) Process for the purification of 1-(4-chlorophenyl)pyrazol-3-ol
WO2017125504A1 (fr) Formes polymorphes de tert-butanolate de bromhydrate de vortioxétine
WO2015087343A2 (fr) Procédé amélioré pour la préparation de nilotinib et de sels pharmaceutiquement acceptables de celui-ci
JP6275596B2 (ja) テルミサルタンのアンモニウム塩の製造方法
WO2016206662A1 (fr) Hémisulfate d'ibrutinib
CN107406372A (zh) 米诺环素碱的新的多晶型形式及其制备方法
EP4188905B1 (fr) Procédé de purification de trifénatate de vilantérol
WO2014136126A2 (fr) Procédé pour la préparation de forme a du chlorhydrate d'erlotinib
JP6622634B2 (ja) ミルタザピンの製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20181214

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20191122

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603